It was certainly noted that the share price had a spike at the...

First 42 Last

Share
Profile

Follow
RussianTex

229 Posts.

47

02/02/22

12:30

Post #: 59299050
Share

Originally posted by GoldenHunter: ↑

Like many pil shareholders we believed the CR was going to keep the price at 2cents support.
This position did not prevail, in fact it was the worst decision the company had made, duping sophisticated investors into the rare sighting of 2.5cents.

This capital raise was a catastrophic failure, bad timing, and look at where we are now
A sobering price correction at 1cents.

There's obviously alot of steam with shareholders vs shareholders trying to manipulate the price.
But unlike other companies, like WCN asx, rmi asx their capital raise did not drastically change the share price.

Now we received the long awaited Quarterly, where every other user has provided their delusional perspectives of the company and how great its positioned, when in fact its a boneless fish of a report, it's all deals and no substance or performance on the part of peppermint progress .

Now the Emi license would not change sentiment of share price because the quarterly proved the undeniable fact that the company struggles to turn a profit.
. How do you think it'll fair with a Emi license, and issuing loans to untested customers??

But like many of you, we still holding onto line of hope eventhough the captains henchman have aborted the mission and the ship is sinking....

When I read through these comments on this panel it's all sunshine and rainbows, no one user offers the reality... It's sickening commentary

Expand

It was certainly noted that the share price had a spike at the right time. Just when they are making a placement. I think when you are investing in a penny stock you can't have everything. There will always be significant risks to justify the potential for significant rewards.

PIL Price at posting: 1.3¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 46 more messages in this thread...

First 42 Last

Add PIL (ASX) to my watchlist

(20min delay)
Last 0.7¢		Change 0.000(0.00%)		Mkt cap ! $14.84M

Open	High	Low	Value	Volume
0.7¢	0.7¢	0.7¢	$681	97.31K

Buyers (Bids)

No.	Vol.	Price($)
21	13285846	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	293673	1

View Market Depth

No.	Vol.	Price($)
21	13285846	0.006
13	12506433	0.005
6	13750000	0.004
6	18166670	0.003
4	9300006	0.002

Price($)	Vol.	No.
0.007	293673	1
0.008	4310822	9
0.009	5692296	11
0.010	7951124	12
0.011	7420090	7

Last trade - 13.38pm 07/10/2024 (20 minute delay)

PIL (ASX) Chart

It was certainly noted that the share price had a spike at the...

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

It was certainly noted that the share price had a spike at the...

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News